Seeking Alpha

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make...

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make sense if the chatter is true that the company is lined up as an acquisition target by Big Pharma, according to Michael Morhamus. Unfazed by the stock's 510% YTD return on the promise of its breast cancer treatment, he notes that institutional money avoids "highly promoted" stocks like GALE.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs